SABCS 2021 | Autologous macrophages with an anti-HER2 CAR in HER2 overexpressing solid tumors

Chimeric antigen receptor (CAR) T-cell approaches have led to remarkable advances in the treatment of patients with hematologically malignancies but not yet within solid tumors. In this interview, Yara Abdou, MD, University of North Carolina, Chapel Hill, NC, discusses an ongoing first-in-human Phase I study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in patients with HER2-overexpressing solid tumors. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.